A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind

Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.

Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.

drug development
Targeting Proteins and Proteolysis to Counter Cancer
Targeting Proteins and Proteolysis to Counter Cancer
The Scientist Creative Services Team | Oct 20, 2020
Daohong Zhou and Aileen Frost explore how they target the proteolysis mechanism and fight cancer using proteolysis targeting chimera (PROTAC) technology.
Western Blot Protein Detection: Enzymatic vs. Fluorescence Methods
Western Blot Protein Detection: Enzymatic vs. Fluorescence Methods
The Scientist Creative Services Team | Sep 25, 2020
Download this article to learn how to pick the best detection technique for your protein research!
Antibody-Based Drug May Reduce COVID-19 Hospitalizations: Study
Antibody-Based Drug May Reduce COVID-19 Hospitalizations: Study
Lisa Winter | Sep 17, 2020
Eli Lilly reports a 72 percent reduction in hospitalization risk among patients who received its monoclonal antibody compared to those who received a placebo.
New Drug Combo for ALS Slows Decline in Small Clinical Study
New Drug Combo for ALS Slows Decline in Small Clinical Study
Jef Akst | Sep 3, 2020
After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo.
Doctors Forge Ahead with Plasma for COVID-19, Benefits Uncertain
Doctors Forge Ahead with Plasma for COVID-19, Benefits Uncertain
Shawna Williams | Aug 14, 2020
Researchers say the popularity of convalescent plasma makes it more difficult to gather high-quality data on its efficacy.
Russia Approves World’s First Coronavirus Vaccine
Russia Approves World’s First Coronavirus Vaccine
Jef Akst | Aug 11, 2020
Some researchers express skepticism given the lack of data about the vaccine’s safety and efficacy, and the country plans to vaccinate healthcare workers, teachers, and others even before testing is complete.
Activities Discovered for Some Inactive Drug Ingredients
Activities Discovered for Some Inactive Drug Ingredients
Ruth Williams | Jul 23, 2020
Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.
Special Report
Seeking an Early COVID-19 Drug, Researchers Look to Interferons
Seeking an Early COVID-19 Drug, Researchers Look to Interferons
Alakananda Dasgupta | Jul 20, 2020
These antiviral proteins are produced by the body as a natural defense against viral infections and synthetic interferons might help prevent or treat the beginning stages of SARS-CoV-2 infection.
Remdesivir Shows Promise in Largest of Several Clinical Trials
Remdesivir Shows Promise in Largest of Several Clinical Trials
Catherine Offord | Apr 30, 2020
Gilead’s experimental antiviral drug shortened the average time it took COVID-19 patients to recover in a NIAID-sponsored trial. There was weak evidence that it also helped reduce deaths.